TY - JOUR
T1 - Complications from stereotactic body radiotherapy for lung cancer
AU - Kang, Kylie H.
AU - Okoye, Christian C.
AU - Patel, Ravi B.
AU - Siva, Shankar
AU - Biswas, Tithi
AU - Ellis, Rodney J.
AU - Yao, Min
AU - Machtay, Mitchell
AU - Lo, Simon S.
N1 - Publisher Copyright:
© 2015 by the authors; licensee MDPI, Basel, Switzerland.
PY - 2015
Y1 - 2015
N2 - Stereotactic body radiotherapy (SBRT) has become a standard treatment option for early stage, node negative non-small cell lung cancer (NSCLC) in patients who are either medically inoperable or refuse surgical resection. SBRT has high local control rates and a favorable toxicity profile relative to other surgical and non-surgical approaches. Given the excellent tumor control rates and increasing utilization of SBRT, recent efforts have focused on limiting toxicity while expanding treatment to increasingly complex patients. We review toxicities from SBRT for lung cancer, including central airway, esophageal, vascular (e.g., aorta), lung parenchyma (e.g., radiation pneumonitis), and chest wall toxicities, as well as radiation-induced neuropathies (e.g., brachial plexus, vagus nerve and recurrent laryngeal nerve). We summarize patient-related, tumor-related, dosimetric characteristics of these toxicities, review published dose constraints, and propose strategies to reduce such complications.
AB - Stereotactic body radiotherapy (SBRT) has become a standard treatment option for early stage, node negative non-small cell lung cancer (NSCLC) in patients who are either medically inoperable or refuse surgical resection. SBRT has high local control rates and a favorable toxicity profile relative to other surgical and non-surgical approaches. Given the excellent tumor control rates and increasing utilization of SBRT, recent efforts have focused on limiting toxicity while expanding treatment to increasingly complex patients. We review toxicities from SBRT for lung cancer, including central airway, esophageal, vascular (e.g., aorta), lung parenchyma (e.g., radiation pneumonitis), and chest wall toxicities, as well as radiation-induced neuropathies (e.g., brachial plexus, vagus nerve and recurrent laryngeal nerve). We summarize patient-related, tumor-related, dosimetric characteristics of these toxicities, review published dose constraints, and propose strategies to reduce such complications.
UR - http://www.scopus.com/inward/record.url?scp=84935038274&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84935038274&partnerID=8YFLogxK
U2 - 10.3390/cancers7020820
DO - 10.3390/cancers7020820
M3 - Review article
AN - SCOPUS:84935038274
SN - 2072-6694
VL - 7
SP - 981
EP - 1004
JO - Cancers
JF - Cancers
IS - 2
ER -